Table 3.
Summary of the potential therapeutic targets that arise due to genetic aberrations frequently occurring in uLMS.
| Aberration | Frequency | Therapeutic Target | Potential Drugs |
|---|---|---|---|
| TP53 | 26–92% | Mutant p53 [90] | APR-246 [91] |
| WEE-1 [95] | AZD1775/MK-1775 [103,107] | ||
| RB1 | 27–88% | AURKA [109,110] | MLN8237/Alisertib [113,114,117] |
| E2F [108] | HLM006474 [118,119] | ||
| ATRX | 24–34% | ATR | VE-821 [141], VX-970, AZD6738 |
| EZH2 [139,148,149] BLM PCNA PARP WEE-1 |
Tazemetostat, GSK-126 ML216 [142] T2AA [143] PJ34 [147] AZD1775 [144,145] |
||
| PTEN | 19–75% | PI3K [163,164] | AZD6482 [162], Buparlisib |
| AKT [163,164] | MK-2206 [162], AZD5363 | ||
| mTORC1 [163,164] SRC FAK |
Temsirolimus [162,166], Everolimus, Ridaforolimus [165] Dasatinib [172] VS-4718, VS-6063, PF-573228, PF-562271, GSK2256098 [168] |
||
| PARP | KU0058948 [174], Olaparib [175] | ||
| MED12 | 12–21% | TGF-βR | LY2157299 [185] |
| BET [193] | JQI | ||
| HRD | 7–60% | PARP [78,81,202] | Olaparib [59,60] |